Back to Search
JAVIER ENRIQUE CARLES M.D.
M.D.
Family Medicine Physician
NPI: 1508809344IndividualAccepts Medicare
Specialties, Licenses & Credentials
Family Medicine PhysicianPrimary
Family Medicine
Code: 207Q00000X
22639(SC)
Education
UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE
Class of 1998
Research & Publications (20)
Orthotopic liver transplantation with vena cava preservation and suprahepatic caval anastomosis.
PMID 10850608·Ann Transplant·2000
8-other
Phase II study of vinorelbine and estramustine in combination with conformational radiotherapy for patients with high-risk prostate cancer.
PMID 19577864·Int J Radiat Oncol Biol Phys·2010
3-trial
Impact of PSA implementation and combined radiation and hormonal therapy (RT+HT) on outcome of prostate cancer patients.
PMID 19625182·Eur J Cancer·2009
4-observational
Predictive modelling in hormone-refractory prostate cancer (HRPC).
PMID 19211372·Clin Transl Oncol·2009
8-other
Expression of cyclooxygenase-2 mRNA in peripheral blood of head and neck cancer patients and in healthy controls. A pilot study.
PMID 17364333·Acta Otolaryngol·2007
8-other
Weekly administration of docetaxel in combination with estramustine and celecoxib in patients with advanced hormone-refractory prostate cancer: final results from a phase II study.
PMID 17955053·Br J Cancer·2007
3-trial
Gemcitabine and oxaliplatin combination: a multicenter phase II trial in unfit patients with locally advanced or metastatic urothelial cancer.
PMID 17693649·Ann Oncol·2007
3-trial
Present strategies in the treatment of metastatic renal cell carcinoma: an update on molecular targeting agents.
PMID 17092282·BJU Int·2007
6-review
Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy.
PMID 17229776·Ann Oncol·2007
8-other
Single-nucleotide polymorphisms in base excision repair, nucleotide excision repair, and double strand break genes as markers for response to radiotherapy in patients with Stage I to II head-and-neck cancer.
PMID 16979838·Int J Radiat Oncol Biol Phys·2006
3-trial
Feasiblity study of gemcitabine and cisplatin administered every two weeks in patients with advanced urothelial tumors and impaired renal function.
PMID 17074675·Clin Transl Oncol·2006
4-observational
Risk-adapted management for patients with clinical stage I seminoma: the Second Spanish Germ Cell Cancer Cooperative Group study.
PMID 16260698·J Clin Oncol·2005
3-trial
Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.
PMID 16275937·J Clin Oncol·2005
3-trial
Her-2/neu expression in prostate cancer: a dynamic process?
PMID 15269147·Clin Cancer Res·2004
8-other
Multicenter study evaluating a dual policy of postorchiectomy surveillance and selective adjuvant single-agent carboplatin for patients with clinical stage I seminoma.
PMID 12796024·Ann Oncol·2003
4-observational
Gemcitabine and carboplatin in advanced transitional cell carcinoma of the urinary tract: an alternative therapy.
PMID 12712469·Cancer·2003
3-trial
Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine.
PMID 12209718·Cancer·2002
3-trial
Gaucher's disease and fatal hepatic fibrosis despite prolonged enzyme replacement therapy.
PMID 12042560·Pediatrics·2002
5-case
Phase II multicentre study of docetaxel plus cisplatin in patients with advanced urothelial cancer.
PMID 11875692·Br J Cancer·2002
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
Via LEXINGTON HEALTH INC · 2 locations total
- Address
- 557 COLUMBIA AVE STE B
CHAPIN, SC 29036 - Phone
- (803) 345-3414
Quick Facts
- NPI
- 1508809344
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 2
- Years in Practice
- 28
- Publications
- 20
Are you this provider?
Claim Your Profile